IN2014CN03042A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN03042A IN2014CN03042A IN3042CHN2014A IN2014CN03042A IN 2014CN03042 A IN2014CN03042 A IN 2014CN03042A IN 3042CHN2014 A IN3042CHN2014 A IN 3042CHN2014A IN 2014CN03042 A IN2014CN03042 A IN 2014CN03042A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- erbb3
- bind
- certain embodiments
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161541312P | 2011-09-30 | 2011-09-30 | |
US201161557460P | 2011-11-09 | 2011-11-09 | |
US201261614565P | 2012-03-23 | 2012-03-23 | |
PCT/US2012/056446 WO2013048883A2 (en) | 2011-09-30 | 2012-09-21 | Anti-erbb3 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN03042A true IN2014CN03042A (de) | 2015-07-03 |
Family
ID=46970445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3042CHN2014 IN2014CN03042A (de) | 2011-09-30 | 2012-09-21 |
Country Status (21)
Country | Link |
---|---|
US (5) | US8791244B2 (de) |
EP (1) | EP2760893B1 (de) |
JP (2) | JP6271432B2 (de) |
KR (1) | KR20140069331A (de) |
CN (1) | CN103917562B (de) |
AR (1) | AR088171A1 (de) |
AU (2) | AU2012316402B2 (de) |
BR (1) | BR112014007382A2 (de) |
CA (1) | CA2849508C (de) |
CL (1) | CL2014000758A1 (de) |
CO (1) | CO6940383A2 (de) |
EA (2) | EA201791393A3 (de) |
ES (1) | ES2694153T3 (de) |
HK (1) | HK1200468A1 (de) |
IL (2) | IL231318B (de) |
IN (1) | IN2014CN03042A (de) |
MX (1) | MX357391B (de) |
SG (1) | SG11201400150TA (de) |
TW (2) | TW201809012A (de) |
WO (1) | WO2013048883A2 (de) |
ZA (1) | ZA201401424B (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS54795B1 (sr) | 2009-12-22 | 2016-10-31 | Roche Glycart Ag | Anti-her3 antitela i njihova korišćenja |
EA201791393A3 (ru) | 2011-09-30 | 2018-03-30 | Ридженерон Фармасьютикалз, Инк. | Антитела к erbb3 и их применение |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
CA2856297C (en) | 2011-11-23 | 2023-10-17 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
CN104755499B (zh) | 2012-11-08 | 2020-10-02 | 霍夫曼-拉罗奇有限公司 | 结合HER3 β-发夹和HER4 β-发夹的抗HER3/HER4抗原结合蛋白 |
CN105263523A (zh) * | 2013-03-15 | 2016-01-20 | 米尔纳疗法公司 | 使用微rna和egfr-tki抑制剂的联合癌症治疗 |
US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
WO2015058108A1 (en) * | 2013-10-17 | 2015-04-23 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
KR102127408B1 (ko) | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
CN106459212B (zh) | 2014-02-28 | 2021-07-13 | 美勒斯公司 | 结合erbb-2和erbb-3的抗体 |
ES2816624T3 (es) * | 2014-02-28 | 2021-04-05 | Merus Nv | Anticuerpos que se unen a EGFR y ERBB3 |
WO2015157634A1 (en) * | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
EP3169354A4 (de) * | 2014-07-17 | 2018-06-13 | Brian J. Czerniecki | Identifikation von immunogenen mhc-klasse-ii-peptiden für immunbasierte therapie |
CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
CA2959775A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
AU2016307943A1 (en) | 2015-08-14 | 2018-02-15 | Allergan, Inc. | Heavy chain only antibodies to PDGF |
ES2865482T3 (es) | 2015-10-23 | 2021-10-15 | Merus Nv | Moléculas de unión que inhiben el crecimiento del cáncer |
KR101746152B1 (ko) * | 2015-12-07 | 2017-06-13 | 주식회사 이수앱지스 | ErbB3에 특이적으로 결합하는 항체 및 그의 용도 |
US20180362654A1 (en) | 2015-12-11 | 2018-12-20 | Regeneron Pharmaceuticals, Inc. | Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade |
SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
JP6729926B2 (ja) * | 2016-05-12 | 2020-07-29 | 国立大学法人神戸大学 | ErbB3活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法 |
CN110475569B (zh) | 2017-02-28 | 2023-11-21 | 第一三共株式会社 | Egfr-tki耐受性的非小细胞肺癌的治疗剂以及抗her3抗体-药物偶联物的应用 |
EA201992063A1 (ru) | 2017-03-31 | 2020-03-26 | Мерус Н.В. | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 |
CN111094351A (zh) | 2017-08-09 | 2020-05-01 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
CN107860925B (zh) * | 2017-11-03 | 2019-07-12 | 合肥瀚科迈博生物技术有限公司 | 用于检测血清中HuA21抗体的ELISA检测试剂盒 |
WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
KR20210062005A (ko) | 2018-09-20 | 2021-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료 |
WO2020072937A1 (en) * | 2018-10-04 | 2020-04-09 | The Trustees Of The University Of Pennsylvania | Antibodies against basement membrane zone adhesion proteins bp180 and bp230 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ES2191702T3 (es) | 1994-03-17 | 2003-09-16 | Merck Patent Gmbh | Fv monocatenarios anti-egfr y anticuerpos anti-egfr. |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
EP0896586B2 (de) | 1996-03-27 | 2015-05-20 | Genentech, Inc. | ErbB3 ANTIKÖRPER |
EP1053009B1 (de) | 1998-02-04 | 2004-09-22 | Genentech, Inc. | Verwendung des heregulins als epithelzellenwachstumsfaktor |
US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
EP1228766A1 (de) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 Phosphorylierung durch HER3 induziert Tumorinvasion |
EP1417232B1 (de) | 2001-06-13 | 2014-12-03 | Genmab A/S | Humane monoklonale antikörper gegen den epidermal-growth-factor-rezeptor (egfr) |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
WO2002102972A2 (en) * | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
EP1283053A1 (de) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitore der HER3 Aktivität |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
EP2263691B1 (de) | 2002-07-15 | 2012-08-29 | F.Hoffmann-La Roche Ag | Behandlung von Krebs mit dem rekombinanten, humanisierten, monoklonalen Anti-ERBB2-Antikörper 2C4 (rhuMAb 2C4) |
WO2004079434A2 (en) | 2003-02-28 | 2004-09-16 | Northwestern University | Vapor deposited electro-optic films self-assembled through hydrogen bonding |
ME00425B (me) * | 2003-05-30 | 2011-10-10 | Genentech Inc | Liječenje sa anti-vegf antitijelima |
WO2005079434A2 (en) | 2004-02-17 | 2005-09-01 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
US7723484B2 (en) * | 2005-11-12 | 2010-05-25 | Applied Molecular Evolution, Inc. | Anti-EGFR antibodies |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
PT2374818E (pt) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | Anticorpos com elevada afinidade para o receptor il-6 humano |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
ES2431940T3 (es) | 2007-02-16 | 2013-11-28 | Merrimack Pharmaceuticals, Inc. | Anticuerpos contra la ERBB3 y usos de los mismos |
EP2138511A1 (de) | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 als Determinante für eine Melanomprognose |
CA2732658A1 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
MX2011007684A (es) * | 2009-01-19 | 2011-08-08 | Abbott Lab | Agentes inductores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes. |
WO2010085845A1 (en) | 2009-01-28 | 2010-08-05 | The University Of Queensland | Cancer therapy and/or diagnosis |
RU2504553C2 (ru) * | 2009-03-20 | 2014-01-20 | Дженентек, Инк. | Антитела к her |
AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
EA201200195A1 (ru) | 2009-08-21 | 2012-12-28 | Мерримаск Фармасьютикалс, Инк. | АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ |
AU2010303443A1 (en) * | 2009-10-09 | 2012-04-19 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-Her 3 antibodies |
EP2496600A1 (de) | 2009-11-04 | 2012-09-12 | Fabrus LLC | Verfahren zur optimierung von antikörpern auf der basis von affinitätsreifung |
EP3670539A1 (de) | 2009-11-13 | 2020-06-24 | Daiichi Sankyo Europe GmbH | Material und verfahren zur behandlung oder vorbeugung von her-3-assoziierten erkrankungen |
RS54795B1 (sr) * | 2009-12-22 | 2016-10-31 | Roche Glycart Ag | Anti-her3 antitela i njihova korišćenja |
EP3072904A1 (de) * | 2010-03-02 | 2016-09-28 | Abbvie Inc. | Therapeutische dll4-bindende proteine |
NZ602084A (en) | 2010-03-11 | 2014-07-25 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
CN102884085B (zh) | 2010-04-09 | 2016-08-03 | Aveo制药公司 | 抗erbb3抗体 |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
PE20140230A1 (es) | 2010-08-20 | 2014-02-26 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3) |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
EA201791393A3 (ru) | 2011-09-30 | 2018-03-30 | Ридженерон Фармасьютикалз, Инк. | Антитела к erbb3 и их применение |
TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗-egfr抗體及其用途 |
-
2012
- 2012-09-21 EA EA201791393A patent/EA201791393A3/ru unknown
- 2012-09-21 EA EA201490717A patent/EA028879B1/ru not_active IP Right Cessation
- 2012-09-21 US US13/623,885 patent/US8791244B2/en active Active
- 2012-09-21 SG SG11201400150TA patent/SG11201400150TA/en unknown
- 2012-09-21 CA CA2849508A patent/CA2849508C/en active Active
- 2012-09-21 WO PCT/US2012/056446 patent/WO2013048883A2/en active Application Filing
- 2012-09-21 JP JP2014533618A patent/JP6271432B2/ja active Active
- 2012-09-21 AU AU2012316402A patent/AU2012316402B2/en active Active
- 2012-09-21 ES ES12768988.3T patent/ES2694153T3/es active Active
- 2012-09-21 MX MX2014003711A patent/MX357391B/es active IP Right Grant
- 2012-09-21 IN IN3042CHN2014 patent/IN2014CN03042A/en unknown
- 2012-09-21 EP EP12768988.3A patent/EP2760893B1/de active Active
- 2012-09-21 KR KR1020147011692A patent/KR20140069331A/ko not_active Application Discontinuation
- 2012-09-21 CN CN201280045274.1A patent/CN103917562B/zh not_active Expired - Fee Related
- 2012-09-21 BR BR112014007382A patent/BR112014007382A2/pt not_active IP Right Cessation
- 2012-09-27 AR ARP120103601A patent/AR088171A1/es unknown
- 2012-09-28 TW TW106116405A patent/TW201809012A/zh unknown
- 2012-09-28 TW TW101135734A patent/TW201329103A/zh unknown
-
2014
- 2014-02-25 ZA ZA2014/01424A patent/ZA201401424B/en unknown
- 2014-03-05 IL IL231318A patent/IL231318B/en not_active IP Right Cessation
- 2014-03-27 CL CL2014000758A patent/CL2014000758A1/es unknown
- 2014-04-30 CO CO14092568A patent/CO6940383A2/es active IP Right Grant
- 2014-06-18 US US14/308,527 patent/US9284380B2/en active Active
-
2015
- 2015-01-28 HK HK15100956.5A patent/HK1200468A1/xx unknown
-
2016
- 2016-02-01 US US15/011,978 patent/US9827310B2/en active Active
-
2017
- 2017-04-12 IL IL251697A patent/IL251697A0/en unknown
- 2017-07-18 AU AU2017206185A patent/AU2017206185B2/en active Active
- 2017-10-25 US US15/793,756 patent/US10632194B2/en active Active
- 2017-12-26 JP JP2017248591A patent/JP6563472B2/ja active Active
-
2020
- 2020-04-14 US US16/848,752 patent/US11771762B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN03042A (de) | ||
PH12019501393A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
MX2013004761A (es) | Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas. | |
PH12016501186A1 (en) | Anti-cd3 antibodies and methods of use | |
MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
MY178142A (en) | Anti-phf-tau antibodies and their uses | |
MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
MY173839A (en) | Cd37-binding molecules and immunoconjugates thereof | |
NZ706189A (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
IN2014DN08721A (de) | ||
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
IN2014DN09228A (de) | ||
GB201109238D0 (en) | Antibodies | |
MX2012013875A (es) | Anticuerpos de union sparc en sangre periferica y usos de los mismos. | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
MX343580B (es) | Anticuerpos contra el g-csfr y sus usos. | |
MX2015010023A (es) | Anticuerpos anti-cd83 y su uso. | |
MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. | |
MX2013011596A (es) | Anticuerpos que se unen a tgf-alfa y epiregulina. | |
CR20200160A (es) | ANTICUERPOS ANTI-CD3 Y MÉTODOS DE USO (Divisional 2016-0314) |